Maturing pipeline supported by very strong balance sheet Group revenues 160 M , equal to guidance Group net loss 8.1 M Year-end cash 141.5 M, excluding 6.0 M in milestone receivables for 2013 revenues and also excluding 33 M under the CIR program of the French government Expansions of GLPG0634 franchise with AbbVie for Phase 2 studies in RA & ... (more)
More...
More...